• Je něco špatně v tomto záznamu ?

1-Year Outcomes of the CENTERA-EU Trial Assessing a Novel Self-Expanding Transcatheter Heart Valve

D. Tchétché, S. Windecker, AM. Kasel, U. Schaefer, S. Worthley, A. Linke, M. Abdel-Wahab, H. Le Breton, L. Søndergaard, MS. Spence, S. Petronio, H. Baumgartner, T. Hovorka, P. Blanke, H. Reichenspurner,

. 2019 ; 12 (7) : 673-680. [pub] 20190408

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, multicentrická studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20022783

OBJECTIVES: The purpose of this study is to report the 1-year results of the CENTERA-EU trial. BACKGROUND: The CENTERA transcatheter heart valve (THV) (Edwards Lifesciences, Irvine, California) is a low-profile (14-F eSheath compatible), self-expanding nitinol valve, with a motorized delivery system allowing for repositionability. The 30-day results of the CENTERA-EU trial demonstrated the short-term safety and effectiveness of the valve. METHODS: Implantations were completed in 23 centers in Europe, Australia, and New Zealand. Transfemoral access was used in all patients. Echocardiographic outcomes were adjudicated by a core laboratory at baseline, discharge, 30 days, 6 months, and 1 year. Major adverse clinical events were adjudicated by an independent clinical events committee. RESULTS: Between March 2015 and July 2016, 203 high-risk patients (age 82.7 ± 5.5 years, 67.5% women, 68.0% New York Heart Association functional class III or IV, Society of Thoracic Surgeons score 6.1 ± 4.2%) with severe, symptomatic aortic stenosis underwent transcatheter aortic valve replacement with the CENTERA THV. The primary endpoint of the study was 30-day mortality (1.0%). At 1 year, overall mortality was 9.1%, cardiovascular mortality was 4.6%, disabling stroke was 4.1%, new permanent pacemakers were implanted in 6.5% of patients at risk, and cardiac-related rehospitalization was 6.8%. Hemodynamic parameters were stable at 1 year, with a mean aortic valve gradient of 8.1 ± 4.7 mm Hg, a mean effective orifice area of 1.7 ± 0.42 cm2, and no incidences of severe or moderate aortic regurgitation. CONCLUSIONS: The CENTERA-EU trial demonstrated mid-term safety and effectiveness of the CENTERA THV, with low mortality, sustained improvements in hemodynamic performances, and low incidence of permanent pacemaker implantations in high-risk patients with symptomatic aortic stenosis. (Safety and Performance of the Edwards CENTERA-EU Self-Expanding Transcatheter Heart Valve [CENTERA-2]; NCT02458560).

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20022783
003      
CZ-PrNML
005      
20201214124814.0
007      
ta
008      
201125s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jcin.2019.01.231 $2 doi
035    __
$a (PubMed)30947942
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Tchétché, Didier $u Groupe Cardiovasculaire Interventionnel, Clinique Pasteur, Toulouse, France. Electronic address: d.tchetche@clinique-pasteur.com.
245    10
$a 1-Year Outcomes of the CENTERA-EU Trial Assessing a Novel Self-Expanding Transcatheter Heart Valve / $c D. Tchétché, S. Windecker, AM. Kasel, U. Schaefer, S. Worthley, A. Linke, M. Abdel-Wahab, H. Le Breton, L. Søndergaard, MS. Spence, S. Petronio, H. Baumgartner, T. Hovorka, P. Blanke, H. Reichenspurner,
520    9_
$a OBJECTIVES: The purpose of this study is to report the 1-year results of the CENTERA-EU trial. BACKGROUND: The CENTERA transcatheter heart valve (THV) (Edwards Lifesciences, Irvine, California) is a low-profile (14-F eSheath compatible), self-expanding nitinol valve, with a motorized delivery system allowing for repositionability. The 30-day results of the CENTERA-EU trial demonstrated the short-term safety and effectiveness of the valve. METHODS: Implantations were completed in 23 centers in Europe, Australia, and New Zealand. Transfemoral access was used in all patients. Echocardiographic outcomes were adjudicated by a core laboratory at baseline, discharge, 30 days, 6 months, and 1 year. Major adverse clinical events were adjudicated by an independent clinical events committee. RESULTS: Between March 2015 and July 2016, 203 high-risk patients (age 82.7 ± 5.5 years, 67.5% women, 68.0% New York Heart Association functional class III or IV, Society of Thoracic Surgeons score 6.1 ± 4.2%) with severe, symptomatic aortic stenosis underwent transcatheter aortic valve replacement with the CENTERA THV. The primary endpoint of the study was 30-day mortality (1.0%). At 1 year, overall mortality was 9.1%, cardiovascular mortality was 4.6%, disabling stroke was 4.1%, new permanent pacemakers were implanted in 6.5% of patients at risk, and cardiac-related rehospitalization was 6.8%. Hemodynamic parameters were stable at 1 year, with a mean aortic valve gradient of 8.1 ± 4.7 mm Hg, a mean effective orifice area of 1.7 ± 0.42 cm2, and no incidences of severe or moderate aortic regurgitation. CONCLUSIONS: The CENTERA-EU trial demonstrated mid-term safety and effectiveness of the CENTERA THV, with low mortality, sustained improvements in hemodynamic performances, and low incidence of permanent pacemaker implantations in high-risk patients with symptomatic aortic stenosis. (Safety and Performance of the Edwards CENTERA-EU Self-Expanding Transcatheter Heart Valve [CENTERA-2]; NCT02458560).
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a aortální chlopeň $x diagnostické zobrazování $x patofyziologie $x chirurgie $7 D001021
650    _2
$a aortální stenóza $x diagnostické zobrazování $x mortalita $x patofyziologie $x chirurgie $7 D001024
650    12
$a bioprotézy $7 D001705
650    _2
$a ženské pohlaví $7 D005260
650    12
$a srdeční chlopně umělé $7 D006350
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a pooperační komplikace $x mortalita $x terapie $7 D011183
650    _2
$a prospektivní studie $7 D011446
650    _2
$a protézy - design $7 D011474
650    _2
$a obnova funkce $7 D020127
650    _2
$a rizikové faktory $7 D012307
650    _2
$a stupeň závažnosti nemoci $7 D012720
650    _2
$a časové faktory $7 D013997
650    _2
$a transkatetrální implantace aortální chlopně $x škodlivé účinky $x přístrojové vybavení $x mortalita $7 D065467
650    _2
$a výsledek terapie $7 D016896
651    _2
$a Austrálie $7 D001315
651    _2
$a Evropa $7 D005060
651    _2
$a Nový Zéland $7 D009520
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Windecker, Stephan $u Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
700    1_
$a Kasel, A Markus $u Department of Cardiovascular Diseases, German Heart Center, Munich, Germany.
700    1_
$a Schaefer, Ulrich $u Department of Cardiology, Marienkrankenhaus, Hamburg, Germany.
700    1_
$a Worthley, Stephen $u Department of Cardiovascular Medicine, Royal Adelaide Hospital, Adelaide Australia.
700    1_
$a Linke, Axel $u Department of Internal Medicine and Cardiology, Herzzentrum Dresden, Universitätsklinik an der Technischen Universität Dresden, Dresden, Germany.
700    1_
$a Abdel-Wahab, Mohamed $u Cardiology Department, Heart Center and Leipzig Heart Institute, University of Leipzig, Leipzig, Germany.
700    1_
$a Le Breton, Herve $u Service de Cardiologie, CHU Rennes, Rennes, France; U1099, INSERM, Rennes, France; LTSI, Université de Rennes 1, Rennes, France.
700    1_
$a Søndergaard, Lars $u Cardiology Department, Rigshospitalet, Copenhagen, Denmark.
700    1_
$a Spence, Mark S $u Cardiology Department, Royal Victoria Hospital, Belfast, United Kingdom.
700    1_
$a Petronio, Sonia $u Cardiothoracic and Vascular Department, Ospedale di Cisanelo, Pisa, Italy.
700    1_
$a Baumgartner, Helmut $u Department of Cardiology III: Adult Congenital and Valvular Heart Disease, University Hospital Muenster, Münster, Germany.
700    1_
$a Hovorka, Tomas $u Statistics Department, Edwards Lifesciences, Prague, Czech Republic.
700    1_
$a Blanke, Philipp $u Department of Radiology, University of British Columbia, Vancouver, Canada.
700    1_
$a Reichenspurner, Hermann $u Department of Cardiovascular Surgery, University Heart Center, Hamburg, Germany.
773    0_
$w MED00186218 $t JACC. Cardiovascular interventions $x 1876-7605 $g Roč. 12, č. 7 (2019), s. 673-680
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30947942 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201214124814 $b ABA008
999    __
$a ok $b bmc $g 1595102 $s 1113459
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 12 $c 7 $d 673-680 $e 20190408 $i 1876-7605 $m JACC. Cardiovascular interventions $n JACC Cardiovasc Interv $x MED00186218
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Možnosti archivace